Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Pizzuti

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
Oncotargets and Therapy|May 23, 2019
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?Marina Elena Cazzaniga, Laura Biganzoli, Laura Cortesi, et al.
Scientific Reports|October 8, 2016
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomesAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Journal of Cellular Physiology|December 18, 2016
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast CancerAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Cells|July 24, 2019
Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast CancerAngela Maselli, Stefania Parlato, Rossella Puglisi, et al.
Journal of Cancer|April 12, 2014
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational studyTeresa Gamucci, Andrea Michelotti, Laura Pizzuti, et al.
Oncotarget|December 17, 2017
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?Andrea Botticelli, Concetta Elisa Onesti, Ilaria Zizzari, et al.
Journal of Cancer|November 26, 2019
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future ScenariosLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Oncotarget|July 30, 2014
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumabPatrizia Vici, Francesca Sperati, Marcello Maugeri-Saccà, et al.
Scientific Reports|August 16, 2017
Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expressionAnna Di Benedetto, Cristiana Ercolani, Marcella Mottolese, et al.
Vaccines|April 25, 2020
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need TrialAndrea Botticelli, Silvia Mezi, Giulia Pomati, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Oncotargets and Therapy|May 23, 2019
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?Marina Elena Cazzaniga, Laura Biganzoli, Laura Cortesi, et al.
Scientific Reports|October 8, 2016
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomesAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Journal of Cellular Physiology|December 18, 2016
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast CancerAnna Di Benedetto, Marcella Mottolese, Francesca Sperati, et al.
Cells|July 24, 2019
Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast CancerAngela Maselli, Stefania Parlato, Rossella Puglisi, et al.
Journal of Cancer|April 12, 2014
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational studyTeresa Gamucci, Andrea Michelotti, Laura Pizzuti, et al.
Oncotarget|December 17, 2017
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?Andrea Botticelli, Concetta Elisa Onesti, Ilaria Zizzari, et al.
Journal of Cancer|November 26, 2019
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future ScenariosLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Oncotarget|July 30, 2014
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumabPatrizia Vici, Francesca Sperati, Marcello Maugeri-Saccà, et al.
Scientific Reports|August 16, 2017
Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expressionAnna Di Benedetto, Cristiana Ercolani, Marcella Mottolese, et al.
Vaccines|April 25, 2020
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need TrialAndrea Botticelli, Silvia Mezi, Giulia Pomati, et al.
Pageof 12